JP2023536570A5 - - Google Patents
Info
- Publication number
- JP2023536570A5 JP2023536570A5 JP2023501206A JP2023501206A JP2023536570A5 JP 2023536570 A5 JP2023536570 A5 JP 2023536570A5 JP 2023501206 A JP2023501206 A JP 2023501206A JP 2023501206 A JP2023501206 A JP 2023501206A JP 2023536570 A5 JP2023536570 A5 JP 2023536570A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- protein
- immunogenic composition
- tissue
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063048279P | 2020-07-06 | 2020-07-06 | |
| US63/048,279 | 2020-07-06 | ||
| US202163161136P | 2021-03-15 | 2021-03-15 | |
| US63/161,136 | 2021-03-15 | ||
| PCT/US2021/040392 WO2022010813A2 (en) | 2020-07-06 | 2021-07-03 | Enhancing immune responses through targeted antigen expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023536570A JP2023536570A (ja) | 2023-08-28 |
| JP2023536570A5 true JP2023536570A5 (https=) | 2024-07-29 |
Family
ID=79553731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023501206A Pending JP2023536570A (ja) | 2020-07-06 | 2021-07-03 | 抗原のターゲティング発現による免疫応答の増強法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230241203A1 (https=) |
| EP (1) | EP4175674A4 (https=) |
| JP (1) | JP2023536570A (https=) |
| CN (1) | CN116171168A (https=) |
| WO (1) | WO2022010813A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114315990B (zh) * | 2022-03-10 | 2022-05-27 | 北京康乐卫士生物技术股份有限公司 | 新型冠状病毒特异性单克隆抗体的制备及其应用 |
| CN114949194B (zh) * | 2022-04-08 | 2023-11-28 | 国科宁波生命与健康产业研究院 | 一种用于治疗SARS-CoV-2病毒感染的多肽制剂 |
| WO2025101949A1 (en) * | 2023-11-09 | 2025-05-15 | The Regents Of The University Of California | Engineered phage-based therapeutic compositions and uses thereof |
| WO2025260044A1 (en) * | 2024-06-13 | 2025-12-18 | Rutgers, The State University Of New Jersey | Ligand-directed gene editing approaches |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2361000T3 (es) * | 2004-04-28 | 2011-06-13 | The Trustees Of The University Of Pennsylvania | Suministro secuencial de moléculas inmunogénicas mediante administraciones de un adenovirus y de un virus adeno-asociado. |
| US7959928B2 (en) * | 2004-10-05 | 2011-06-14 | Cytos Biotechnology Ag | VLP-antigen conjugates and their uses as vaccines |
| EP3058370A4 (en) * | 2013-10-14 | 2017-08-30 | The University of North Carolina at Chapel Hill | Methods and compositions for coronavirus diagnostics and therapeutics |
| GB201519303D0 (en) * | 2015-11-02 | 2015-12-16 | Imp Innovations Ltd | Phagemid vector |
| AU2020357866A1 (en) * | 2019-10-04 | 2022-04-21 | Rutgers, The State University Of New Jersey | Targeted pulmonary delivery compositions and methods using same |
-
2021
- 2021-07-03 EP EP21837275.3A patent/EP4175674A4/en active Pending
- 2021-07-03 CN CN202180052561.4A patent/CN116171168A/zh active Pending
- 2021-07-03 US US18/004,517 patent/US20230241203A1/en active Pending
- 2021-07-03 WO PCT/US2021/040392 patent/WO2022010813A2/en not_active Ceased
- 2021-07-03 JP JP2023501206A patent/JP2023536570A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023536570A5 (https=) | ||
| JP2023512519A5 (https=) | ||
| JP2021512126A5 (https=) | ||
| JP2020203894A5 (https=) | ||
| JP2022115876A5 (https=) | ||
| US8293717B2 (en) | Materials and methods for prevention and treatment of RNA viral diseases | |
| JP2023519640A5 (https=) | ||
| JP2025184979A5 (https=) | ||
| JP2023527791A5 (https=) | ||
| US20230241203A1 (en) | Enhancing immune responses through targeted antigen expression | |
| JP2004501646A5 (https=) | ||
| JP2023126658A5 (https=) | ||
| JP2024537250A5 (https=) | ||
| JP2025501746A5 (https=) | ||
| JP2005508158A5 (https=) | ||
| JP2007516214A5 (https=) | ||
| JP2023548205A5 (https=) | ||
| JP2020522249A5 (https=) | ||
| JP2023529124A5 (https=) | ||
| KR20250067065A (ko) | 재조합 sfts 바이러스 기반 2가 백신 조성물 | |
| JP2018536428A5 (https=) | ||
| JP2025514630A5 (https=) | ||
| JP2025508059A5 (https=) | ||
| JP2024518548A5 (https=) | ||
| US20160228531A1 (en) | Treatment of hepatitis d virus infections by redirection of t cells |